跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
東 雅惠
副教授
藥學系
https://orcid.org/0000-0003-0748-7993
電話
02-28267986
電子郵件
ydong3
ym.edu
tw
h-index
h10-index
h5-index
858
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
582
引文
13
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
157
引文
7
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2011
2024
每年研究成果
概覽
指紋
網路
研究成果
(43)
類似的個人檔案
(6)
指紋
查看啟用 Yaa-Hui Dong 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Confidence Interval
54%
Hazard Ratio
54%
Chronic Obstructive Pulmonary Disease
46%
Population-based Cohort Study
40%
Inhaled Corticosteroids
30%
Statins
28%
Type 2 Diabetic Patients
28%
Hospitalization
26%
Type 2 Diabetes Mellitus (T2DM)
25%
Taiwan
24%
Propensity Score Matching
19%
Glucagon-like
19%
A1 Receptor
19%
Receptor Agonist
19%
Systematic Meta-analysis
19%
Selective Serotonin Reuptake Inhibitors
19%
Multi-database
19%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
17%
Warfarin
16%
Pharmacy
16%
Beta-blockers
16%
Long-acting β2-agonist
15%
Meta-analysis
14%
Long-acting muscarinic Antagonist
13%
Comorbidity
13%
Fixed-dose Combination
12%
Cardiovascular Safety
12%
Comparative Safety
12%
Concomitant Use
12%
Medication Adherence
12%
Meta-analysis of Randomized Controlled Trials
12%
Fluoroquinolones
12%
Clinical Characteristics
12%
Invasive Breast Cancer
12%
Middle-aged Adults
12%
Elderly Adults
12%
Survival Prognosis
12%
Adult Female
12%
Lifestyle Characteristics
12%
Breast Cancer Patients
12%
5-year Survival
12%
Population-based
12%
Risk Reduction
9%
Heart Failure Hospitalization
9%
New User
9%
Cardioselective
9%
High Risk
9%
Mortality Risk
8%
Cardiovascular Outcomes
8%
National Cohort Study
8%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Chronic Obstructive Lung Disease
70%
Non Insulin Dependent Diabetes Mellitus
38%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
30%
Comorbidity
22%
Disease
21%
Statin (Protein)
20%
Selective Serotonin Reuptake Inhibitor
19%
Glucagon Like Peptide 1 Receptor Agonist
19%
Sodium Glucose Cotransporter 2 Inhibitor
17%
Warfarin
15%
Muscarinic Receptor Blocking Agent
14%
Quinolone Derivative
12%
Randomized Controlled Trial
12%
Infection
12%
Bronchodilating Agent
12%
Brain Ischemia
12%
Brain Hemorrhage
10%
Heart Infarction
9%
Calcium Channel Blocker
8%
Atrial Fibrillation
8%
Chronic Disease
8%
Heart Failure
8%
Dry Powder Inhaler
7%
Cardiovascular Disease
7%
Sulfonylurea
7%
Case-Control Study
6%
Pharmacoepidemiology
6%
Acarbose
6%
Fibric Acid Derivative
6%
Acute Coronary Syndrome
6%
Clopidogrel
6%
Lung Cancer
6%
Antithrombotic Therapy
6%
Tamoxifen
6%
Cancer Incidence
6%
Liver Injury
6%
Influenza A
6%
Aortic Dissection
6%
Rheumatoid Arthritis
6%
Beclometasone
6%
Aortic Aneurysm
6%
Thiazolidinedione
6%
Abscess
6%
Aortic Regurgitation
6%
Anemia
6%
Tumor Necrosis Factor Inhibitor
6%
Biological Product
6%
Nutritional Deficiency
6%
Fragility Fracture
6%
Medicine and Dentistry
Cohort Analysis
45%
Hazard Ratio
28%
Patient with Type 2 Diabetes
20%
Chronic Obstructive Pulmonary Disease
19%
Maturity Onset Diabetes of the Young
19%
Glucagon-Like Peptide-1 Agonist
19%
Sodium Glucose Cotransporter 2 Inhibitor
17%
Cardiovascular System
14%
Breast Cancer
13%
Middle Age
12%
Retrospective Cohort Study
8%
Meta-Analysis
7%
Cancer Incidence
7%
Cancer Therapy
7%
Sulfonylurea
7%
Disease
6%
Acarbose
6%
Biological Product
6%
Infection
6%
Roux-en-Y Gastric Bypass
6%
TNF Inhibitor
6%
Cancer in Young Adults
6%
Acute Coronary Syndrome
6%
Hepatitis C
6%
Limb
6%
Fragility Fracture
6%
Hepatitis B
6%
Rheumatoid Arthritis
6%
Olmesartan
6%
Liver Cirrhosis
6%
Nutritional Deficiency
6%
Systematic Review
6%
Bronchodilating Agent
6%
Muscarinic Antagonist
6%
Calcium Channel Blocking Agent
6%
Anemia
6%
Selective Serotonin Reuptake Inhibitor
6%
Thiazolidinedione
6%
Nonsteroid Antiinflammatory Agent
6%
Patient with Hypertension
6%
Abscess
6%
Heart Failure
6%
Enteropathy
6%
Tamoxifen
6%
Radiation Therapy
6%
Cancer Research
6%
Proportional Hazards Model
6%
Propensity Score Matching
5%
